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Background: The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial showed that survival in patients
with severe lower limb ischemia (rest pain, tissue loss) who survived postintervention for >2 years after initial
randomization to bypass surgery (BSX) vs balloon angioplasty (BAP) was associated with an improvement in subsequent
amputation-free and overall survival of about 6 and 7 months, respectively. We now compare the effect on hospital costs
and health-related quality of life (HRQOL) of the BSX-first and BAP-first revascularization strategies using a within-trial
cost-effectiveness analysis.
Methods: We measured HRQOL using the Vascular Quality of Life Questionnaire (VascuQol), the Short Form 36
(SF-36), and the EuroQol (EQ-5D) health outcome measure up to 3 years from randomization. Hospital use was
measured and valued using United Kingdom National Health Service hospital costs over 3 years. Analysis was by
intention-to-treat. Incremental cost-effectiveness ratios were estimated for cost per quality-adjusted life-year (QALY)
gained. Uncertainty was assessed using nonparametric bootstrapping of incremental costs and incremental effects.
Results:No significant differences inHRQOL emergedwhen the two treatment strategies were compared. During the first
year from randomization, the mean cost of inpatient hospital treatment in patients allocated to BSX ($34,378) was
estimated to be about $8469 (95% confidence interval, $2,417-$14,522) greater than that of patients allocated to BAP
($25,909). Owing to increased costs subsequently incurred by the BAP patients, this difference decreased at the end of
follow-up to $5521 ($45,322 for BSX vs $39,801 for BAP) and was no longer significant. The incremental cost-
effectiveness ratio of a BSX-first strategy was $184,492 per QALY gained. The probability that BSX was more
cost-effective than BAP was relatively low given the similar distributions in HRQOL, survival, and hospital costs.
Conclusions: Adopting a BSX-first strategy for patients with severe limb ischemia does result in a modest increase in
hospital costs, with a small positive but insignificant gain in disease-specific and generic HRQOL. However, the
real-world choice between BSX-first and BAP-first revascularization strategies for severe limb ischemia due to infrain-
guinal disease cannot depend on costs alone and will require a more comprehensive consideration of individual patient
preferences conditioned by expectations of survival and other health outcomes. (J Vasc Surg 2010;51:43S-51S.)Severe leg ischemia (SLI), characterized by rest/night
pain and tissue loss due to ulceration or gangrene, leads to
significant morbidity and mortality and also to the con-
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doi:10.1016/j.jvs.2010.01.076sumption of considerable health and social care resources in
developed and developing countries. The absence of level 1
evidence from randomized controlled trials (RCTs) has led
to continuing debate and disagreement about the best
treatment for such patients.1
The United Kingdom (UK)-based, multicenter Bypass
versus Angioplasty in Severe Ischaemia of the Leg (BASIL)
trial was funded by the UK National Institute of Health
Research (NIHR) Health Technology Assessment (HTA)
program (http://www.hta.ac.uk/) in 1998 and remains
the only RCT to compare the clinical and cost-effectiveness
of a bypass surgery (BSX)-first and a balloon angioplasty
(BAP)-first revascularization strategy for SLI caused by
infrainguinal disease.
When the entire follow-up period was considered,
there was no significant difference in amputation-free sur-
vival (AFS) or overall survival (OS) between the two treat-
ments. However, for those patients surviving 2 years from
randomization, a BSX-first revascularization strategy was
associated with a reduced hazard ratio of 0.85 (95% confi-
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AFS and of 0.61 (95% CI, 0.50-0.75; P  .009) for
subsequent OS in an adjusted, time-dependent Cox pro-
portional hazards model. For those patients who survived
for 2 years after randomization, initial randomization to a
BSX-first revascularization strategy was associated with an
increase in subsequent restricted mean OS of 7.3 months
(95% CI, 1.2-13.4 months; P  .02) and an increase in
restricted mean AFS of 5.9 months (95% CI, 0.2-12.0
months, P .06) during the subsequentmean follow-up of
3.1 years (range, 1-5.7).2,3
Although AFS was the primary trial end point, other
important consequences of the chosen revascularization
strategy included the effect on hospital costs and the pa-
tients’ perceptions of their health-related quality of life
(HRQOL). We integrated the prospective definition and
measurement of these secondary end points into the design
of the BASIL trial to allow a more comprehensive consid-
eration of the primary factors that might influence the
choice between BSX-first and BAP-first revascularization
strategies.
METHODS
The BASIL trial is registered with the National Research
Register (NRR) and as an International Standard Randomized
Controlled Trial, number ISRCTN 45398889 (http://www.
controlled-trials.com/ISRCTN45398889/45398889).
The methods of the BASIL trial have been reported
previously.2,3 The BASIL trial design integrated measure-
ment of survival, AFS, HRQOL, and the use of hospital
inpatient services. These trial outcomes allowed consider-
ation of the primary health and resource consequences after
the two different revascularization strategies. Individual
patient hospital costs were collected to the end of follow-
up. All analyses were by intention-to-treat using the per-
spective of the individual patient for HRQOL and the UK
hospital sector for resource use.
Health-related quality of life. We measured HRQOL
using the Vascular Quality of Life Questionnaire (VascuQol),4
the generic Short Form 36 (SF-36) health survey,5 and
utility scores based on the EuroQoL 5-D (EQ-5D).6
Higher scores on the VascuQol, SF-36 scales and summary
scores, and EQ-5D indicate better health and well-being as
perceived by the patient. These measures were collected
using a self-administered protocol at baseline (randomiza-
tion) and at 3, 6, 12, 24, and 36 months after randomiza-
tion. All patients were asked to provide HRQOL data out
to 3 years from randomization, whether or not they had
undergonemajor amputation of the trial leg.
The VascuQol is a disease-specific questionnaire de-
signed to assess specific elements of HRQOL for individu-
als with lower limb ischemia. It includes 25 items (ques-
tions) subdivided into five domains: pain (4 questions),
symptoms (4 questions), activities (8 questions), social (2
questions), and emotional (7 questions). Each question has
a 7-point response scale ranging from 1 (worst possible) to
7 (best possible). Responses were averaged for individualdomain and composite total scores, giving equal weight
to each question and domain.
The SF-36 contains 36 questions that measure
HRQOL across eight domains: physical functioning, social
functioning, role limitations due to physical problems, role
limitations due to emotional problems, mental health (gen-
eral mood or affect including anxiety, depression and
psychological well-being), energy/vitality, bodily pain, and
general health perceptions. For each dimension, question
responses were coded, scored, and transformed into a scale
from0 (worst possible score) to 100 (best possible score). The
SF-36 items were combined into physical andmental compo-
nent summary scores using recommended procedures.7
The SF-6D, a single-index preference-based measure,
was also derived from the SF-36 responses using the Brazier
algorithm.8 This provided a further summary measure of
the SF-36 items using a health state valuation model that
complements the EQ-5D. Because it is based on the
broader and more detailed SF-36 items and has a strong
theoretic and methodologic basis, the SF-6D enabled us to
consider whether the level of and change in patient percep-
tions of well-being after randomization was similar across
these two leading preference-based measures of well-being.
The EQ-5Dindex covers five dimensions: mobility, self-
care, usual activity, pain/discomfort, and anxiety/
depression. Each dimension has three levels (no problem,
some problem, or extreme problem), and participants are
asked to indicate the level that corresponds to their current
level of function or experience on each dimension. The
EQ-5D responses were converted into a single weighted
utility (preference-based) score using the original time
trade-off tariff set.9 This is a standard and well-established
set of preference weights used in clinical and economic
evaluations based on experimental, observational, and
modeling studies using UK populations. Overall self-
rated health status was also collected using the visual
analog scale (EQ-VAS) scores ranging from 0 (worst
health) to 100 (best health).
Calculation of quality-adjusted life-years. Quality-
adjusted life-years (QALYs) were calculated per patient
over 3 years using the EQ-5Dindex. A standard multiplica-
tive model was used to estimate QALYs by the area under
linear interpolation of the EQ-5Dindex trajectory for each
individual using the intervals in months 0 to 3, 3 to 6, 6 to
12, 12 to 24, and 24 to 36. These utility-adjusted survival
time intervals were summed to generate a total QALY score
for each patient. Although we did measure survival 3
years (all patients were monitored for minimum of 3 years
and 54% for 5 years) and did collect someHRQOL data for
a longer time horizon, we chose not to estimate QALYs3
years from randomization due to the incomplete clinical
follow-up coupled with an increase in the proportion of
HRQOL nonresponders.
Missing data due to attrition. We expected that
attrition over time would occur as the horizon for
follow-up increased and that missing scores would become
more prevalent as trial participants died (informative drop-
out) or failed to complete questionnaires (nonresponse).
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overall rate of missing HRQOL data was 32%. We report
analyses using both complete information (case-wise dele-
tion of observations when HRQOL scores were missing)
and information based on imputation of missing EQ-5D
data adjusted for informative dropout. We used an impu-
tation method for missing values, using all available infor-
mation after multivariate imputation by chained equa-
tions10,11 for missing EQ-5Dindex scores that were used in
the QALY analysis.
Inpatient hospital use and cost. Resource use data
were collected after randomization on the index interven-
tion and all subsequent interventions, hospital stays, and
hospital clinic visits. Patient-specific hospital use was mea-
sured using the overall duration of stay for each hospital
inpatient episode and the number of day and outpatient
visits. Acute hospital inpatient days were disaggregated by
surgical and medical specialty (eg, vascular surgery, high-
dependency unit, intensive care unit, cardiology, general
medicine, rehabilitation) based on the reasons for admis-
sion and recorded interventions and procedures. Hospital
activity data were recorded in all participating centers for
each patient. Cumulative hospital episodes, days, and visits
were restricted to 3 years from the date of randomization.
Thesemeasures of hospital resource use were converted
into cost estimates using National Health Service (NHS)
hospital costs derived routinely for Scotland, a region of the
UK that accounted for 142 of 452 randomized patients
(31%) in the trial. The inpatient days, broken down by
specialty, were valued using the average specialty-specific
cost per day obtained from the Scottish system of hospital
cost statistics.12 Day and outpatient visits were costed on a
per diem/attendance basis.
All procedures (surgical, radiologic, and amputations)
were measured using patient-specific anesthetic, operating
theater, and recovery suite times; the number and grades
of medical, nursing, and theater staff; and the specific
procedure-related equipment and consumables. Staff time
was valued using UK national pay scales. Purchase costs
were used to value the typical mix of equipment and
consumables used in the surgical and radiologic proce-
Table I. Vascular Quality of Life questionnaire domain an
points from randomization to angioplasty or bypass surger
Health domain
Baseline, mean (SD) 3 mon, mean
Angioplasty Surgery Angioplasty
(n  214) (n  204) (n  161) (
Activity 2.33 (0.98) 2.45 (1.07) 3.65 (1.56) 3.
Symptoms 3.63 (1.42) 3.73 (1.40) 5.11 (1.22) 5.
Pain 2.34 (1.21) 2.48 (1.30) 4.50 (1.73) 4.
Social 2.83 (1.58) 3.08 (1.82) 4.16 (2.03) 4.
Emotional 3.06 (1.33) 3.13 (1.45) 4.58 (1.60) 4.
Overall 2.79 (1.01) 2.90 (1.10) 4.32 (1.39) 4.
aDoes not include four patients lost to follow-up.dures.Hospital use and procedure costs were calculated on a
price base of financial year 2006/2007 in UK pounds (£).
Costs were converted to US dollars ($) using the 2006
purchasing power parity (PPP) rate of currency conversion
($/£ PPP  0.64). A discount rate of 3.5% recommended
by HerMajesty’s Treasury was used to calculate the present
value of annual costs incurred over 3 years from the date of
randomization. We discounted health effects at 3.5% fol-
lowing current guidance from the National Institute for
Clinical Excellence (NICE)13 suggesting that both costs
and health effects should be discounted using a uniform
rate.
Statistical analysis. Data analysis was performed us-
ing Stata 10 software (StataCorp, College Station, Tex).14
Descriptive statistics were based on completed baseline and
follow-up HRQOL questionnaires for complete cases with
no missing items. Analysis of the EQ-5Dindex was per-
formed using a generalized estimating equation model to
adjust for correlated scores measured over time. Imputa-
tions for missing EQ-5Dindex scores were generated using
an algorithm for creating models for imputation (Stata
packages pred_eq and check_eq and the Stata ice pack-
age).14 Summary statistics for costs are based on all pa-
tients, with no allowance for right-censored cases. We
report marginal costs (differences in cumulative costs over 3
years) using an ordinary least squares estimator. Given the
anticipated skewness (a heavy right-hand tail) of the length
of stay and cost data, we also used generalized median
regression estimators that are more robust with respect to
outliers with extremely high cost profiles.
Effectiveness was measured using mean differences in
AFS (the primary end point of the trial), mean differences in
OS, and patient-specific total QALYs to 3 years based on
the EQ-5D. Incremental cost-effectiveness ratios were es-
timated using the mean difference in hospital cost and the
mean difference in effectiveness between the BAP and BSX
groups. To capture the uncertainty surrounding the esti-
mate of mean differences in costs and effects, we used
scatter plots of incremental costs and effects and a 90%
confidence ellipse based on a nonparametric bootstrap
erall scores by intention-to-treat analysis at different time
12 mon, mean (SD) 36 mon, mean (SD)
ry Angioplasty Surgery Angioplasty Surgery
53) (n  132) (n  121) (n  46) (n  49)
.49) 3.79 (1.57) 3.93 (1.55) 3.85 (1.65) 3.71 (1.72)
.16) 5.28 (1.18) 5.35 (1.27) 5.43 (1.13) 5.16 (1.23)
.68) 4.65 (1.72) 4.84 (1.73) 4.78 (1.50) 4.58 (1.73)
.83) 4.43 (1.95) 4.64 (1.77) 4.33 (1.85) 4.20 (2.08)
.54) 4.90 (1.68) 5.06 (1.54) 5.00 (1.63) 4.86 (1.79)
.30) 4.53 (1.42) 4.67 (1.37) 4.61 (1.41) 4.44 (1.55)d ov
ya
(SD)
Surge
n  1
87 (1
33 (1
72 (1
45 (1
80 (1
55 (1technique calculated using 1000 resamples of the difference
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nal sample of patients.
RESULTS
The VascuQol. The disease-specific VascuQol pro-
vides evidence that BSX and BAP both have a positive effect
on all domains affected by SLI (Table I).15 Although
patients allocated to BSX reported slightly better scores at
baseline, the overall pattern was very similar over time and
between groups. Most of the improvement occurred 3
months of randomization, with very little change thereaf-
ter. This sustained positive effect, particularly in the pain
and symptom domains, was maintained over time.
SF-36 health domains and summary scores. SF-36
domains and summary scores are reported in Table II.
Scores before randomization, based on 213 of 224 re-
sponders (95%) in the BAP group and on 207 of 228
responders (91%) in the BSX group, were very similar in the
two trial arms. BASIL patients perceived their health to be
much lower than that reported in general populations
matched for age and gender and in patients undergoing
endovascular or conventional aortic aneurysm repair.16
Large floor effects (proportion of patients in the worst
possible health states) were observed for the role physical
(82%) and role emotional (61%) scales. With the exception
of role emotional (29%), ceiling effects (proportion of
patients in the best possible heath state) were small and well
below 10% for most scales. Patients in both treatment
Table II. Unadjusted Short Form-36 domain scores by in
randomization to angioplasty or bypass surgerya
SF-36 domains
Baseline, mean (SD)
Angioplasty (n  212) Surge
Physical functioning 22.69 (19.39) 23.0
Social functioning 40.63 (28.36) 44.2
Role physical 10.26 (25.49) 13.1
Role emotional 31.45 (42.77) 36.2
Mental health 58.87 (22.73) 60.0
Energy/vitality 34.15 (20.78) 36.3
Bodily pain 30.40 (21.68) 31.9
General health 49.14 (19.81) 48.0
aDoes not include four patients lost to follow-up.
Table III. EuroQol and Short Form-6D scores by intenti
randomization to angioplasty or bypass surgerya
Variable
Baseline, mean (SD) 3 mon, mean (SD
Angioplasty Surgery Angioplasty Sur
(n  214) (n  203) (n  162) (n 
EQ-5D 0.26 (0.32) 0.28 (0.34) 0.53 (0.31) 0.57
EQ VAS 0.53 (0.21) 0.55 (0.21) 0.60 (0.20) 0.62
SF-6D 0.53 (0.10) 0.54 (0.11) 0.60 (0.13) 0.61
EQ-5D, EuroQol weighted index score; EQ VAS, visual analog scale; SF-6D
aDoes not include four patients lost to follow-up.groups reported improved SF-36 domain and summaryscores by 3 months, but little further improvement was
recorded. Most of the gains in SF-36 were concentrated in
the scales that capture perceptions of physical well-being.
However, there was also slight improvement over a longer
time period in the SF-36 mental health domain.
EuroQol (EQ-5D). This general pattern of improve-
ment was also reflected in the EuroQol and SF-6D
weighted index scores (Table III). Although there was
weak evidence that utility scores might be somewhat better
in the BSX group, patients in both treatment groups re-
ported virtually identical levels and trajectories in the
EQ-5D over time. Scores were improved at 3 months and
sustained to 3 years without significant differences between
the BSX-first and BAP-first groups. A similar pattern was
recorded for EQ VAS scores and utility scores based on the
SF-6D, suggesting a high degree of concordance among
these alternative measures of self-reported well-being.
Effect of EQ-5D informative dropout and non-
response. Patient death (informative dropout) and pa-
tient failure to respond at one or more time intervals
(nonresponse) accounted for missing HRQOL data. Pa-
tients who died were given an EQ-5D score of 0 to allow
for informative dropout. The response rates for those eligi-
ble were 93%, 77%, 70%, 44%, and 35%, respectively, at
baseline, 3 months, and at 1, 2, and 3 years after random-
ization, giving an overall response rate of 68%. Response
rates were similar in the two trial arms, and the pattern of
missing information was virtually identical across the other
on-to-treat analysis at different time points from
3 mon, mean (SD)
 204) Angioplasty (n  162) Surgery (n  152)
9.91) 30.77 (25.44) 32.43 (26.55)
1.37) 55.32 (31.58) 57.81 (30.92)
8.99) 25.46 (38.56) 23.03 (36.00)
4.29) 51.65 (45.21) 49.78 (45.07)
1.42) 65.93 (19.84) 68.55 (20.38)
0.81) 42.28 (24.21) 44.61 (23.48)
2.90) 55.21 (27.92) 57.31 (27.96)
1.51) 50.06 (20.67) 52.37 (22.22)
-treat analysis at different time points from
12 mon, mean (SD) 36 mon, mean (SD)
Angioplasty Surgery Angioplasty Surgery
) (n  132) (n  119) (n  48) (n  49)
) 0.56 (0.31) 0.62 (0.28) 0.61 (0.25) 0.54 (0.35)
) 0.60 (0.20) 0.64 (0.19) 0.63 (0.21) 0.61 (0.19)
) 0.63 (0.13) 0.63 (0.12) 0.64 (0.14) 0.60 (0.15)
rt Form weighted index score.tenti
ry (n
4 (1
4 (3
1 (2
7 (4
8 (2
2 (2
7 (2
4 (2on-to
)
gery
152
(0.28
(0.19
(0.13
, ShoHRQOL questionnaires.
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EQ-5D scores were detected when the distribution of
EQ-5D was assessed using a base case, allowing for infor-
mative dropout only, and an alternative based on informa-
tive dropout and multiple imputation for missing data for
nonresponders. At 2 and 3 years, the mean imputed
EQ-5D scores were about 0.10 higher compared against
scores allowing only for informative dropout. This would
be expected given the higher proportion of zeros (or
deaths) in the more restricted analysis that only allowed for
informative dropout (ie, complete cases and deaths).
EQ-5D–imputed scores were also consistently lower
for individuals who underwent an amputation 3 years of
randomization. Although closely matched at baseline,
EQ-5D imputed scores by 3months were 0.06 lower in the
amputee group. This difference remained very steady
throughout the follow-up period.
The generalized estimating equation analysis showed
that EQ-5D–imputed scores were better for up to 3 years in
the BSX-first group (Fig 1). This small but statistically
insignificant advantage in favor of BSX was also detected
when the analysis was restricted to patients with complete
Fig 1. EuroQol-5D scores, up to 36 months after randomization
at baseline, are based on multiple imputation of missing informa-
tion. CI, Confidence interval.
Table II. Continued
12 mon, mean (SD)
Angioplasty (n  132) Surgery (n  119)
33.60 (24.51) 37.39 (29.21)
59.85 (26.63) 61.97 (29.85)
30.11 (39.41) 31.51 (38.85)
52.02 (45.17) 58.82 (42.23)
68.67 (21.41) 70.52 (18.85)
41.21 (23.88) 47.56 (21.62)
54.29 (25.78) 60.04 (27.53)
48.96 (21.79) 50.76 (20.01)data or informative missing data.Hospital admissions, length of stay, and cost. The
use of inpatient hospital services over time was broadly
similar for patients in both trial arms, as measured by the
number of hospital admissions and total days in the hospi-
tal. Over 3 years, both groups had an average of three
hospital stays, and the average length of stay, cumulated
over all inpatient admissions, was just 2 months. During
the first year from randomization, length of stay was shorter
in the BAP-first group, with a mean (interquartile range) of
37 days (4-46 days) vs 45 days (12-60 days) for BSX-first.
In years 2 to 3, the difference in hospital stay shifted in favor
of BSX because the BAP patients used a further 20 days vs
15 days in the BSX. By 3 years, there was only a small (3
days) and insignificant difference in the mean (interquartile
range) length of hospital stay between the two groups, with
57 days (8-73 days) for BAP vs 60 days (16-82 days) for
BSX. Given the additional short-term morbidity of BSX,
there was less of a difference between the two groups than
might perhaps have been expected.
These data, however, encompassed all hospital admis-
sions, not just those directly related to the index admission.
Patients randomized to BAP had a significantly higher
immediate failure and reintervention rate, plus there are a
range of medical and social factors, other than the status of
the trial leg and its treatment, that determine admission and
length of stay in hospital.
Inpatient episodes primarily occurred in ward settings
with relatively little use of the more specialized services
provided in high dependency units (HDU) and intensive
therapy units (ITU). Patients randomized to a BSX-first
strategy used an average of about half a day more of HDU
than did BAP-first patients. There was a slight difference in
ITU use, with a few additional hours used by the BSX-first
patients. The main cost driver remained the number and
duration of episodes in acute ward settings. After 3 years’
follow-up, operating room/angiography suite costs ac-
counted for 9% of total hospital costs in the BAP-first
group; as expected, the corresponding figure was higher, at
14%, for the BSX-first group. Most of the operating room/
angiography suite and hospital ward costs occurred in the
36 mon, mean (SD)
Angioplasty (n  48) Surgery (n  49)
35.10 (27.76) 31.94 (30.05)
61.98 (27.53) 56.12 (36.10)
26.56 (42.65) 25.51 (39.36)
55.56 (47.31) 46.94 (46.61)
70.33 (20.71) 67.18 (20.22)
44.79 (24.28) 44.59 (25.14)
56.94 (25.07) 55.10 (31.51)
48.21 (18.46) 46.51 (21.34)first year after randomization.
JOURNAL OF VASCULAR SURGERY
May Supplement 201048S Forbes et alDuring the first year from randomization, the esti-
mated mean cost of inpatient hospital treatment in patients
randomized to BSX was $34,378 ($28,701 hospital stay
and $5677 procedure costs), which was approximately
one-third higher than the $25,909 ($22,605 hospital stay
and $3305 procedure costs) for patients randomized to
BAP. This difference in mean total hospital and procedures
costs of about $8469 was significant (95% CI, $2434-
$14,505) at 1 year. However, owing to increased costs
incurred by the BAP patients, this difference in total hospi-
tal and procedures costs at the end of 3 years decreased to
$5521 ($45,322 BSX vs $39,801 BAP) and was no longer
significant.
The distribution of costs in both groups was also
skewed with a long, right-hand tail. Costs were$175,000
in 10 patients (7 in the BAP group, 3 in the BSX group).
Table IV reports the marginal effect on total cumulative
cost when more robust estimation methods were used.
Adjusting for outliers using generalized median regression
had an important effect when costs were analyzed during 3
years of follow-up because less weight was given to patients
with extremely high costs, many of whom were in the
BAP-first group. This had the effect of increasing the
estimated cost differences to $9132, which wasmuch closer
to the estimated difference in median costs of $11,507.
AFS, OS, and quality-adjusted survival. As reported
elsewhere, there was little difference in AFS or OS between
the two groups when the follow-up period was taken as a
whole.2,3 Up to 3 years, the difference in mean AFS was 12
days (95% CI, 89-64 days), and the difference in mean OS
was 32 days (95%CI,100-37 days). These small differences
in restricted mean AFS and OS, when calculated over 3 years,
favored the BAP group but were not significant.
When combined with patient-specific EQ-5D scores,
these absolute differences in survival led to virtually no
difference in the number of quality-adjusted life (days)
between the two trial arms. The small positive differences in
HRQOL in favor of BSX, asmeasured by EQ-5Dindexwhen
combined with absolute survival in the two groups out to
36 months from randomization, generated a mean quality-
adjusted lifetime of 412 days for BAP and 423 days for BSX.
The mean difference of 11 days (95% CI,42-64 days), or
just 0.03 of a QALY, failed to achieve conventional levels of
Table IV. Difference in cumulative total costs of a surgery
Cumulative costs Least squares
During 1 yr of follow-up $8469a ($2434 - $14,505)
During 3 yrs of follow-up $5521 ($2929 - $13,971)
No. 448
Marginal effects (95% confidence intervals). Positive effects reflect the additi
report the difference in mean cumulative costs. Median regression estimate
aP  .01.
bP  .001.significance.Cost-effectiveness. Incremental cost-effectiveness ra-
tios (ICER) are calculated as the ratio of the difference in
costs between BSX-first and BAP-first strategies to the
difference in effects. However, when the difference in ef-
fects were measured using AFS and OS up to 3 years after
randomization, the ICERs were not only negative but were
also estimated with a great degree of imprecision because
the small differences were centered close to zero. The ICER
point estimate can be estimated with the ratio of the
additional costs of BSX-first strategy to the difference in
QALYs to generate a cost-per QALY of $184,492 ($5521/
0.03). Using the more robust estimates of the difference in
costs reported in Table IV would increase the ICER to
$304,400 ($9132/0.03).
The bootstrapped joint densities of the difference in
cost (BSX  BAP) between the two trial arms and the
difference in QALYs (BSXBAP) out to 3 years are shown
in Fig 2. About half of the distribution (58%) is located in
the upper right quadrant of the graph (more costly and
more effective). A further 33% is located in the upper left
quadrant (more costly and less effective), with 7% in the
Fig 2. Joint density of incremental cost and incremental quality
adjusted life-year (QALY) of surgery compared with angioplasty.
Positive (negative) incremental costs show that surgery is more
(less) costly than angioplasty. Positive (negative) incremental
QALYs show that surgery is more (less) effective than angioplasty.
t compared with angioplasty-first strategy
Estimation method
Robust regression Median regression
$8699b ($6042 - $11,356) $9744b ($4914 - $14,574)
$9132b ($4832 - $13,433) $11507a ($3792 - $19,222)
448 448
osts of a surgery-first strategy. Least squares and robust regression estimates
ased on differences in median cumulative costs.-firs
onal c
s are blower right quadrant (less costly andmore effective) and 2%
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90% confidence ellipse superimposed on this joint distribu-
tion encompassed the upper left quadrant, suggesting that
additional costs of a BSX-first strategy could lead to a slight
decrease in QALYs.
DISCUSSION
As expected, the disease-specific and generic HRQOL
of the BASIL trial cohort was very low at baseline.17-21 No
significant differences between the two trial arms emerged
across a range of generic and disease-specific HRQOL
measures.22 Although patients had a very low HRQOL
before treatment, BSX and BAP both had very similar
effects on short-term gains in HRQOL that were sustained
for at least 3 years after randomization. This plateau effect
probably reflects the fact that the aggregate data are con-
flating two very different groups: patients who keep
their legs23 and those who do not.24-27 As others have
found,28,29 the relative clinical and hemodynamic advan-
tages and disadvantages of a BSX-first vs a BAP-first strat-
egy for managing SLI due to infrainguinal disease do not
seem easily distinguishable by means of disease-specific or
generic HRQOL.30
These results should be interpreted with caution, be-
cause data were missing in about one-third of the patients
eligible to report HRQOL trial end points. Up to 12
months, however, data completeness in BASIL was actually
above that reported in the Project of Ex-Vivo Vein Graft
Engineering via Transfection (PREVENT) III clinical trial,
which measured QOL using VascuQol.31 Response rates
for BASIL compared with PREVENT III reveal a similar
pattern of attrition due to nonresponse over time of 93.3%
vs 92.3% at baseline, 76.0% vs 65.7% at 3 months, and
68.0% vs 62.5% at 12months. Beyond 12months, response
rates were equally low in both trial arms; this is disappoint-
ing but perhaps to be expected given the clinical realities for
these high-risk patients with a range of comorbidities.32-34
Responders were more likely to have an intact trial leg and,
presumably therefore, to exhibit higher levels of generic but
especially disease-specific HRQOL.35-41 Like PREVENT III,
nonresponse was associated with amputation, and this lim-
ited the information available to measure the effects of the
alternative management strategies on HRQOL in this pa-
tient subgroup.
The hospital costs during the first year were approxi-
mately one-third higher with a BSX-first than with a BAP-
first strategy. Although the cost of the BSX procedure itself
is significantly greater than that of BAP, the main difference
in costs between the two strategies is related to the length
of hospital stay, including the greater requirement for
patients undergoing BSX to be cared for within anHDUor
ITU environment. We were unable to quantify the use and
associated costs of health and social services outside the
hospital or costs beyond 3 years related to further interven-
tions arising from SLI. Thus, our results underestimate
some elements of the costs of managing SLI42-44 that arise
from the rehabilitation of amputees. However, the number
of major limb amputations was similar in the two trial arms,so it is reasonable to assume that these additional costs
would also have been roughly the same after BSX and BAP.
The resource costs estimated in this pragmatic vascular
surgery trial accounted for inpatient hospital stay(s) after
randomization up to 3 years. It reflected contemporary
utilization of hospital inpatient services by patients allo-
cated to one of the strategies in BASIL. Although we
believe our estimate of the differences in hospital costs
between these alternative policies is robust, the absolute
and relative differences are primarily a reflection of ob-
served practice in the BASIL trial centers between 1999
and 2007 and the specific resource unit costs applied in our
study. The use of hospital resources and cumulative costs
during year 1 are also broadly similar to recent reports that
consider the distribution of costs over a longer time hori-
zon.42,43 When costs are measured in a more comprehen-
sive way, capturing not only the initial episode of care but
also subsequent readmissions for (often) multiple opera-
tions and procedures, a more accurate estimate of the
resource consequences of caring for patients presenting
with SLI is obtained. Our results are based on the expected
use of resources within a UK NHS context with corre-
sponding levels of pay and prices that may not be easily
generalizable to other health care systems. Costs may also
change over time as novel and possibly more effective
interventions are adopted and a new pattern of service use is
established.
Our findings should be interpreted carefully against the
background of comparisons of resource use for a relatively
small number of patients who present with SLI, undergo
diagnostic imaging, and are selected for some form of
revascularization. This has the inevitable effect of making
inferences that are less precise and reliable than we would
like because BASIL was powered to detect differences in
the primary end points of AFS and OS for a selected
population.
In addition to the challenges of distributions estimated
with a (large) degree of imprecision, we have the attendant
problem of censoring for those patients still alive at 3 years
whose future QOL and resource utilization was not ob-
served. These estimates are based onHRQOL and absolute
mortality over 3 years. We know that the balance of risks
and benefits for BSX vs BAP changes significantly after 2
years for some patients, and this will not be captured
completely by this analysis. Thus, it is possible that longer-
term survival gains might translate into positive differences
in quality-adjusted survival in favor of BSX. However, this
inference is limited because the numbers of patients avail-
able for longer-term analysis is very small and we do not
have HRQOL data beyond 3 years.
CONCLUSIONS
This HRQOL and economic evaluation of BSX-first
and BAP-first revascularization strategies in patients pre-
senting with SLI due to infrainguinal disease can be used to
inform some of the arguments surrounding the relative
advantages and disadvantages of each intervention. BSX
does appear to have a significant effect on the distribution
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effects in some patients. However, when the additional cost
of BSX is compared against the small increase in survival
adjusted for HRQOL, the cost per QALY is relatively high.
As such, there remains a substantial possibility that for some
patients, BSXmay lead to an increase in costs with little and
possibly negative effects on health measured in the short to
medium term. Further studies of the effect of targeted BSX
or BAP for patients facing different survival chances might
identify more efficient use of resources, if less invasive and
less costly interventions are directed towards those who
may not live long enough to benefit from the apparent
survival advantages conferred by a BSX-first strategy.
However, the real-world choice between BSX-first and
BAP-first revascularization strategies for SLI due to infrain-
guinal disease cannot depend upon a consideration of costs
alone. A more comprehensive consideration of individual
patient preferences conditioned by expectations of survival
and other health outcomes will be required.45
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